We read with interest the letter by Dr Krasseman1 regarding anti-inflammatory doses of aspirin used in the acute phase of Kawasaki disease (KD). Indeed, higher doses of aspirin are currently used in the USA (80–100 mg/kg/day), while in Japan a lower dose of 30–50 mg/kg/day is advocated.2–6 Similarly, in the UK, the latter modest dose has been recommended since 20027 ,8 for the acute phase of KD as a number of previous studies have suggested this lower dose is equally as effective, and may be associated with less toxicity.2 ,4 …